Skip to content
thispeptide

Mint Med

Mint Med offers compounded weight and wellness treatments, but its product prices and legal descriptions need reconciliation. A June 2026 FDA letter adds important labeling context.

Review by Leah Garner, clinical-evidence editor · Updated October 2026

The short version

Request a clear prescription, clinical identity and written quote before enrolling. The low-price and rate-lock claims are difficult to assess while linked pages give different semaglutide amounts.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

FDA warning letter on record: Letter 730390 · June 2026

Mint Med is a Cincinnati-based telehealth storefront offering compounded semaglutide, tirzepatide and NAD+, alongside sermorelin therapy. Its terms identify Mint Med LLC, while the clinical consent identifies Glow Medispa doing business as Mint Med. The differing descriptions should be clarified in the patient’s actual agreement rather than treated as proof that the platform itself prescribes or compounds. The program pages emphasize no membership, included doses and ongoing access to a care team, although those broad claims do not fully explain the preparation, administration route or monitoring for every product.

What Mint Med prescribes, by goal

Weight

  • SemaglutideFDA-approved

    Listed by the seller; no price we hold.

    • TirzepatideFDA-approved

      Listed by the seller; no price we hold.

      Current named products include compounded semaglutide and tirzepatide. The public pages correctly state that these preparations are not FDA-approved and are not approved generic equivalents. The product summaries do not clearly establish administration route and complete formulation for each program. Injection supplies on another explainer page should not substitute for the patient’s actual prescription. Ask the clinician why compounding is appropriate, whether an approved option can meet the need and how treatment changes will be assessed. A price advertised at every dose is a financial claim, not a reason to increase the dose.

      Longevity

      • NAD+Compounding conditions apply

        Listed by the seller; no price we hold.

        NAD+ is described as compounded, while the sermorelin page gives a therapy name and purchase period without an equally detailed preparation description. Neither a kit name nor a bottle image establishes route or concentration. Ask for the actual formulation and instructions, the evidence relevant to the intended goal and the planned monitoring. A shared catalog layout does not show that the same suitability criteria or clinical evidence applies to both products.

        Recovery

        • SermorelinCompounding conditions apply

          Listed by the seller; no price we hold.

          Sleep

          • SermorelinCompounding conditions apply

            Listed by the seller; no price we hold.

            Who prescribes

            A licensed clinician

            The service does not name the actual treating clinician or a distinct prescribing medical group on the reviewed pages. It describes independent licensed providers who make treatment decisions after reviewing the patient’s information. The consent allows audio, video and asynchronous communication, which does not establish that every patient receives a live visit. Ask who is responsible for assessment, prescribing and clinical escalation before relying on a general care-team promise. The contact page directs medical questions to a secure patient portal, while customer support handles order and shipping questions separately.

            The product pages say a provider reviews each request, with a business-hours qualification attached to the advertised review time. They also describe round-the-clock care-team access, while the contact page lists more limited customer-support hours and response estimates. Those statements may concern different teams, so confirm how to reach the prescriber when a symptom or dose question needs attention. The consent renews with later telehealth consultations and requires accurate, current medical information. A stable advertised rate does not establish that the same preparation or regimen should continue without reassessment.

            Are labs required?

            Not mentioned

            The reviewed pages do not establish a universal required panel or complete laboratory charge for these programs. Ask whether the clinician needs recent results, whether testing is recommended before treatment and how outside results are reviewed. An included clinical visit or care-team feature does not necessarily include laboratory work. The patient should also know who handles an abnormal result or a condition requiring in-person assessment. Avoid treating a general application approval as evidence that every relevant clinical issue has already been evaluated.

            Ready to start with Mint Med?

            Prices and plans are set on the seller's own site.

            What it claims, and what it cites

            FDA sent Glow Medispa doing business as Mint Med a June 2026 warning following its review of the website in May. The letter concerned misleading compounder identity on pictured labels for compounded semaglutide and tirzepatide. That is an advertising and misbranding record, not a determination that every prescription was contaminated. Current pages expressly acknowledge the medicines’ unapproved compounded status, but that does not itself establish FDA confirmation that the earlier concerns are resolved. The public partner-certification language also does not identify the actual dispensing pharmacy or establish that Mint Med holds each partner’s certification.

            How it bills

            Current semaglutide and tirzepatide product selectors show $89 and $119 billed monthly, while the linked semaglutide explainer quotes $129 month-to-month and site banners show another generic amount. Those statements need a written product-specific reconciliation. Lower semaglutide and tirzepatide equivalents require longer prepaid purchases. NAD+ is listed at $189 billed monthly, while sermorelin says $120 every four weeks despite generic monthly wording nearby. The refund policy requires cancellation at least 48 business hours before processing and can reclaim a promotional discount after an early exit from a prepaid term. Missing product detail should not be filled in by assuming every plan uses the same route or billing clock.

            For and against

            • For: The public pages acknowledge compounded status
            • For: Monthly and prepaid selections can be distinguished
            • For: Cancellation timing and processing cutoffs are stated
            • Against: Linked semaglutide prices conflict
            • Against: Treating clinician and dispensing pharmacy are not identified publicly
            • Against: Product-specific route and preparation details are incomplete
            • Against: A direct FDA labeling warning is relevant

            The evidence behind what it sells

            Right for

            A patient who can obtain a consistent written agreement and verify the actual clinician, pharmacy and preparation before purchase.

            Look elsewhere if

            Someone choosing solely from the lowest prepaid equivalent or interpreting partner-certification claims as identification of the actual dispensing facility.

            Other sellers for weight

            Mint Med

            Frequently asked questions

            Does a rate-lock claim establish the complete prescription?
            No. Route, formulation, quantity and clinical monitoring still need individual confirmation.
            What did the FDA letter concern?
            It addressed misleading compounder identity on pictured labels, not a finding that every patient’s medication was contaminated.
            Does cancellation after processing guarantee a refund?
            No. The public policy treats processed prescriptions as final and requires advance notice before the next processing date.

            Sources

            • Care and treatment: Current semaglutide monthly and prepaid choices
            • Care and treatment: Linked semaglutide explainer with differing monthly quote
            • Care and treatment: Current tirzepatide purchase options
            • Care and treatment: NAD+ purchase claims
            • Care and treatment: Sermorelin period and generic monthly wording
            • Care and treatment: Operator and renewal terms
            • Care and treatment: Clinical consent and operator identity
            • Care and treatment: Advance notice and prepaid exit policy
            • Care and treatment: Cancellation page and form reference
            • Care and treatment: Actual support and dispatch descriptions
            • Care and treatment: FDA direct warning and compounder-label concerns

            See what Mint Med prescribes today

            Mint Med sets its own prices, plans and the states it serves. Check them before you start.

            Written by Leah Garner from Mint Med’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.